反义和RNAi疗法市场（按寡核苷酸类型、给药途径、治疗领域和最终用户划分）—2025-2032年全球预测

预计到 2032 年，反义和 RNAi 疗法市场将成长至 152.3 亿美元，复合年增长率为 15.59%。

将分子创新与反义和RNAi疗法的临床前景结合，以重新定义治疗模式、给药方式和患者疗效。

反义寡核苷酸和RNA干扰（RNAi）疗法正从小众科学研究走向主流治疗方法，影响着多个治疗领域和临床策略。过去十年，化学、递送平台和监管科学的进步，使得从分子概念到临床概念验证和核准产品的路径更加清晰。因此，从小型专业生技公司到大型综合製药公司，相关人员将寡核苷酸平台视为解决传统难治性标靶的核心资产。相应地，研发团队目前正努力在早期创新与生产规模化、安全性评估和以病人为中心的给药方案等实际问题之间取得平衡。

同时，临床项目也不断多元化。研究范围已从罕见遗传疾病扩展到更广泛的治疗领域，在这些领域中，基因表现调控提供了一种差异化的作用机制。这种拓展得益于一些新技术，这些技术能够提高组织标靶性、减少脱靶效应并降低给药频率，增强了反义寡核苷酸和RNA干扰药物的临床和商业性合理性。此外，分析方法和临床前模型的改进也提高了转化研究的信心，并使从研究到临床的转化路径更加快速、迭代。

重要的是，这种不断变化的格局需要整合思维。科学创新必须与供应链韧性、监管协作以及以支付方观点的证据产生相辅相成。随着研发週期缩短和监管路径日益清晰，专案团队必须儘早协调跨职能协作，并以高度严谨的营运执行。本导言为深入探讨重塑该领域的变革性转变、影响全球供应链的政策和贸易动态，以及领导者在设计产品组合和商业化策略时应考虑的实际细分和区域差异奠定了基础。

平台成熟、监管政策明朗化以及协作营运模式正在重塑反义和RNAi产品的开发和商业化路径。

反义和RNAi疗法领域正经历着变革性的转变，这主要得益于平台成熟度、监管政策的明朗化以及更广泛的临床应用目标的共同推动。平台成熟度的提升体现在两个方面：化学设计和偶联策略的进步提高了药物的稳定性和疗效；递送技术的创新则拓展了药物作用范围，使其能够覆盖肝臟以外的组织。这些技术进步降低了标靶选择的传统障碍，使得药物研发计画能够优先考虑患者的便利性和长期依从性。因此，药物研发公司正在积极探索心血管疾病、代谢性疾病和神经退化性疾病等先前在技术和商业性都极具挑战性的适应症。

监管路径也在不断调整，监管机构对寡核苷酸独特的风险获益特征有了更深入的了解。这种理解使得围绕非临床资料包、生物标记策略和安全性监测的对话更加可预测，从而缩短了从早期临床试验到疗效研究的週期。同时，临床试验设计也在不断发展，变得更加灵活和以生物标记主导，从而支持更精准的临床实验群体选择和更清晰的作用机制论证。因此，研发人员从研发初期就开始利用转换终点和真实世界数据（RWE）框架，为支付者建构更具相关性的资料。

商业性和营运行为也与这些科学和监管变化保持同步。研发人员优先考虑生产扩充性和先进的分析技术，以降低CMC活动的风险，同时透过合作和联盟将临床能力与专业的合约开发和生产组织（CDMO）联繫起来。这些合作模式使规模较小的申办者能够在维持对科学的策略控制的同时，利用所需的产业资源来推进后期开发并最终推向市场。这些变化共同拓展了临床可行性的定义，并重塑了研发和商业化领域的策略格局。

评估2025年美国关税对寡核苷酸疗法原料采购、生产物流和全球供应的影响

2025年关税政策环境将对寡核苷酸价值链产生重大影响，该价值链涉及原料采购、特殊试剂和关键耗材的跨境流动。关税将增加进口核苷酸、修饰亚磷酰胺、脂质体配方用脂质以及某些酶的成本，这将给製造商带来即时的成本压力，并可能影响製程规模化和商业化生产位置决策。从长远来看，持续存在的贸易壁垒可能会促使供应链区域化，并投资于国内或邻近地区的生产能力，以降低进口波动带来的风险。

在营运层面，进口成本上升通常会导致采购前置作业时间延长，促使买家整合订单以扩大规模或重新认证多家供应商以实现冗余。这种现象凸显了供应商关係管理、品质监控和库存管理政策的重要性。申办方和契约製造製造商的策略性因应措施可能包括：签订多年合约、投资替代化学技术以减少对高关税风险原料的依赖，或在可行的情况下加快垂直整合策略。此外，还需考虑工艺变更的监管时间表。关键原料的采购可能需要额外的製程验证和监管咨询，这可能会限制临床供应策略的灵活性。

从策略角度来看，关税驱动的改变既带来挑战也带来机会。虽然成本上升会在短期内造成不利影响，但同时也会促使企业投资于国内製造业产能、本地人才培养和流程效率提升，进而增强长期供应链的韧性。此外，政策不确定性的增加通常会提升采购多元化和健全风险管理方案的价值。因此，那些积极建立关税情境模型、将替代方案纳入采购和生产计划并根据需要与政策相关人员沟通的企业，将更有利于在贸易中断的情况下保持发展势头。

细分市场洞察揭示了寡核苷酸类型、递送方法、治疗标靶和最终用户如何影响研发重点和商业化选择。

细分市场分析突显了科学机会与商业性可行性的交会点，理解这些细分市场对于投资优先排序和商业模式设计至关重要。基于寡核苷酸类型的分类将市场划分为反义寡核苷酸和干扰性RNAi。在干扰性RNAi中，进一步区分了微干扰RNA和小干扰RNA，二者在效力、剂量预期和递送方式方面各有不同。这些分子差异决定了化学结构、偶联策略和毒性监测等方面的项目选择，同时也影响组织靶向和生物标记策略的选择。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 新兴的脂质体奈米颗粒递送系统可提高siRNA的稳定性和细胞摄取率。
• 标靶定向寡核苷酸疗法的配体结合平台开发
• 透过将 CRISPR-Cas13 RNA 编辑技术与 RNAi 疗法结合来实现精确的基因静默
• 利用人工智慧优化反义序列设计并进行脱靶预测
• 扩大RNAi药物皮下製剂的给药范围，以提高患者依从性和给药频率
• 针对罕见神经肌肉疾病（存在高度未满足的医疗需求）的反义疗法的临床进展
• 肿瘤学中针对多种疾病路径的多效价siRNA构建体的进展
• 监管协调努力旨在加速新型RNAi疗法的全球核准

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 反义和RNAi疗法市场（以寡核苷酸类型划分）

• 反义寡核苷酸
• 干扰RNAi
  • 微干扰RNA
  • 小干扰RNA

9. 反义和RNAi疗法市场依给药途径划分

• 鞘内给药
• 静脉注射
• 口服
• 皮下注射
• 外用

10. 反义和RNAi疗法市场按治疗领域划分

• 循环系统
• 免疫学
• 代谢性疾病
• 神经系统疾病
• 肿瘤学
• 眼科
• 罕见疾病

第十一章 反义和RNAi疗法市场（按最终用户划分）

• CRO（受託研究机构）
• 製药公司
• 研究所

12. 各地区反义与RNAi疗法市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 反义和RNAi疗法市场（按类别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国反义与RNAi疗法市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Acuitas Therapeutics Inc.
  • Alloy Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Benitec Biopharma Limited
  • City Therapeutics
  • Danaher Corporation
  • Eli Lilly and Company
  • Evox Therapeutics Ltd
  • GenScript Biotech Corporation
  • GSK PLC
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Ribocure Pharmaceuticals AB
  • Sanofi SA
  • Shanghai Argo Biopharmaceutical Co., Ltd.
  • Silence Therapeutics plc
  • Stoke Therapeutics, Inc.
  • Suzhou Ribo Life Science Co., Ltd.
  • Wave Life Sciences Ltd

The Antisense & RNAi Therapeutics Market is projected to grow by USD 15.23 billion at a CAGR of 15.59% by 2032.

Bridging molecular innovation and clinical promise in antisense and RNAi therapeutics to redefine treatment paradigms, delivery, and patient outcomes

Antisense and RNA interference (RNAi) therapeutics are transitioning from a niche scientific pursuit into a mainstream modality influencing multiple therapeutic areas and clinical strategies. Over the past decade, advances in chemistry, delivery platforms, and regulatory science have brought a clearer line of sight from molecular concept to clinical proof of concept, and increasingly to approved products. As a result, stakeholders ranging from small specialized biotechs to large, integrated pharmaceutical companies view oligonucleotide platforms as core assets for addressing previously intractable targets. Consequently, development teams are now balancing early-stage innovation with the practicalities of manufacturing scale, safety characterization, and patient-centric administration.

At the same time, clinical programs are diversifying. Research now extends beyond rare genetic diseases into more prevalent therapeutic segments where modulation of gene expression offers differentiated mechanisms of action. This expansion has been enabled by technologies that improve tissue targeting, reduce off-target effects, and enable lower dosing frequencies, thereby strengthening the clinical and commercial rationale for antisense oligonucleotides and RNAi agents. Further, improvements in analytical methods and preclinical models have increased confidence in translational choices, enabling a faster, more iterative path from bench to clinic.

Importantly, the evolving landscape requires integrated thinking: scientific innovation must be matched by supply chain resilience, regulatory engagement, and payer-forward evidence generation. As development cycles compress and regulatory pathways become better-understood, program teams must orchestrate cross-functional alignment early and execute with heightened operational rigor. This introduction sets the stage for a deeper exploration of the transformative shifts reshaping the field, the policy and trade dynamics that affect global supply chains, and the practical segmentation and regional nuances leaders must account for when designing portfolios and commercialization strategies.

Platform maturation regulatory clarity and collaborative operational models that are reshaping antisense and RNAi product development and commercialization pathways

The antisense and RNAi therapeutic landscape is undergoing transformative shifts driven by convergence of platform maturation, regulatory clarity, and broader clinical ambition. Platform maturation has been twofold: chemistry and conjugate strategies have improved stability and potency, while delivery innovations have extended reach into tissues beyond the liver. These technical advances have reduced historical barriers to target selection and enabled programs that prioritize patient convenience and long-term adherence. As a result, drug developers are increasingly exploring indications in cardiovascular, metabolic, and neurodegenerative diseases that were previously considered technically or commercially infeasible.

Regulatory pathways are also adapting, with agencies demonstrating greater familiarity with oligonucleotide-specific risks and benefit profiles. This familiarity permits more predictable interactions around nonclinical packages, biomarker strategy, and safety monitoring, which, in turn, shortens the cycle from early human trials to pivotal studies. In parallel, clinical trial design is becoming more adaptive and biomarker-driven, supporting enriched patient selection and clearer demonstration of mechanism. Consequently, sponsors are leveraging translational endpoints and real-world evidence frameworks to build payer-relevant dossiers earlier in development.

Commercial and operational behaviors are aligning with these scientific and regulatory shifts. Developers are prioritizing manufacturing scalability and advanced analytics to de-risk CMC activities, while partnerships and alliances link clinical capabilities with specialized contract development and manufacturing organizations. These collaborative structures enable smaller sponsors to retain strategic control of their science while accessing the industrial capabilities necessary to move programs through late-stage development and into the market. Taken together, these shifts are expanding the definition of clinical viability and redefining strategic playbooks across research, development, and commercialization.

Evaluating how 2025 US tariff actions could reshape raw material sourcing, manufacturing logistics, and global supply of oligonucleotide therapeutics

The policy environment created by tariff measures in 2025 has important implications for the oligonucleotide value chain, where raw material sourcing, specialized reagents, and critical consumables traverse international borders. Tariffs that raise the cost of imported nucleotides, modified phosphoramidites, lipids used in lipid nanoparticle formulations, and select enzymes could create immediate cost pressure for manufacturers and impact decisions about where to site process scale-up and commercial production. Over time, sustained trade barriers can encourage greater regionalization of supply chains and foster investment in domestic or nearshore production capacity to mitigate exposure to import volatility.

Operationally, higher import costs will often translate into longer procurement lead times as buyers consolidate orders to achieve scale or requalify multiple suppliers for redundancy. In turn, this behavior places a premium on supplier relationship management, quality oversight, and inventory policies. For sponsors and contract manufacturers, the strategic response may include securing multi-year contracts, investing in alternate chemistries that reduce reliance on tariff-exposed inputs, or accelerating vertical integration strategies where feasible. Regulatory timelines for process changes must also be considered, as re-sourcing critical raw materials can require additional process validation and regulatory communications, potentially constraining the flexibility of clinical supply strategies.

Strategically, tariff-induced shifts can yield both challenge and opportunity. While cost increases present near-term headwinds, they can motivate investments in domestic manufacturing capacity, regional talent development, and improved process efficiencies that strengthen long-term supply resilience. Moreover, policy uncertainty typically increases the value of diversified sourcing and robust risk management programs. Consequently, organizations that proactively model tariff scenarios, incorporate contingency options into procurement and manufacturing plans, and engage with policy stakeholders where appropriate will be better positioned to maintain development momentum despite trade disruptions.

Segmentation insights demonstrating how oligonucleotide type, administration mode, therapeutic targets, and end users shape R&D focus and commercialization choices

Segmentation analysis provides clarity on where scientific opportunity and commercial viability intersect, and understanding these segments is critical for prioritizing investment and operational design. Based on Oligonucleotide Type, the landscape differentiates antisense oligonucleotides and interfering RNAi; within interfering RNAi, programs further distinguish between micro interfering RNAs and small interfering RNAs, each with distinct potency, dosing expectations, and delivery considerations. These molecular distinctions drive program-level choices in chemistry, conjugation strategies, and toxicity monitoring, and also inform the selection of tissue targets and biomarker strategies.

Based on Mode Of Administration, development paths and patient adoption profiles diverge significantly across intrathecal, intravenous, oral, subcutaneous, and topical routes. Administration mode influences formulation science, cold chain and logistics requirements, and the design of clinical operations; for example, intrathecal and intravenous routes often necessitate facility-based administration and more complex safety monitoring, while subcutaneous and oral options support decentralized models that can improve patient retention and real-world uptake. As a result, companies must weigh the trade-offs between clinical efficacy, patient convenience, and the downstream implications for reimbursement and market access.

Based on Therapeutic Areas, program portfolios reflect a breadth of indication choices, spanning cardiovascular, immunology, metabolic disorders, neurological disorders, oncology, ophthalmology, and rare diseases. Each therapeutic area carries unique regulatory expectations, clinical endpoint challenges, and competitive dynamics. For instance, neurology and rare disease programs may rely heavily on validated biomarkers and patient registries, whereas oncology and cardiovascular initiatives may require larger, event-driven trials and differentiated value propositions for payers. Strategic alignment between therapeutic focus and platform strengths is therefore a core determinant of program design and resource allocation.

Based on End User, the market's ecosystem includes contract research organizations, pharmaceutical companies, and research laboratories that collectively shape innovation cycles and commercialization pathways. Contract research organizations play an increasingly central role in providing specialized development and manufacturing capabilities that lower barriers for sponsors. Pharmaceutical companies contribute commercial scale, regulatory expertise, and payer engagement capabilities, while research laboratories drive early discovery and mechanistic understanding. The interplay among these end users determines how capabilities are assembled, how risks are shared, and how innovations ultimately reach patients.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping development hubs, manufacturing, regulations, and patient access

Regional dynamics exert outsized influence on development strategies, manufacturing footprints, and go-to-market planning, with distinct capability clusters emerging across geographies. In the Americas, dense biotech ecosystems and advanced clinical infrastructure support rapid proof-of-concept studies and growing manufacturing networks that prioritize scale and regulatory familiarity. These conditions make the region attractive for late-stage development and commercial launches, while access to venture and public capital continues to drive innovation in platform technologies and first-in-class programs.

In Europe, Middle East & Africa, a mix of academic excellence, regulatory harmonization within certain jurisdictions, and evolving industrial policy encourages partnerships and center-of-excellence models. Sponsors targeting these markets often coordinate multi-jurisdictional regulatory strategies and leverage regional manufacturing hubs to serve multiple neighboring markets efficiently. Policy incentives and public-private collaborations in parts of this region also encourage investment in capacity expansion and advanced analytics.

Across Asia-Pacific, capacity expansion, government-supported industrial initiatives, and a rapidly maturing clinical research environment are reshaping supply and demand dynamics. Increasing local manufacturing capabilities and talent pools create opportunities for nearshore sourcing and regional clinical acceleration. Consequently, many organizations are evaluating hybrid development models that combine western clinical development with Asia-Pacific manufacturing or clinical execution to optimize timelines, cost, and patient recruitment. Taken together, these regional patterns underscore the importance of aligning portfolio design with geographic strengths to optimize development velocity and commercial access.

Competitive and collaborative company strategies alliances and platform investments accelerating pipelines and scaling manufacturing for RNA-based therapies

Company behaviors in the oligonucleotide sector reflect a balance of competition and collaboration, with strategic alliances and platform investments driving acceleration of pipelines and scaling of manufacturing. Leaders in the space are investing in chemistry innovations, conjugate technologies, and delivery systems such as lipid-based carriers or receptor-targeting conjugates to expand tissue reach and improve safety margins. These investments are complemented by selective M&A and partnership activity that brings together discovery capabilities with late-stage development and commercialization resources.

Beyond scientific investments, companies are making deliberate choices about how to structure manufacturing operations. Some sponsors opt to partner with specialized contract development and manufacturing organizations to access scale quickly, while others pursue vertically integrated models to retain greater control over critical process steps and supply security. In either case, investments in analytical capabilities, process automation, and regulatory-ready quality systems are common priorities, as they materially reduce the time and risk associated with scale-up and commercial release.

Collaboration extends to payer and provider engagement as well. Forward-looking companies are modeling long-term value propositions that incorporate dosing convenience, durability of effect, and real-world outcomes to build evidence packages that resonate with health systems. Partnerships that align clinical development with payer expectations and delivery systems enhance the probability of favorable access conditions and smoother rollout strategies. Overall, corporate strategies emphasize platform differentiation, manufacturing resilience, and cross-sector engagement to convert scientific potential into durable clinical and commercial success.

Practical strategic actions for industry leaders to optimize delivery, de-risk development, and accelerate clinical adoption of antisense and RNAi therapies

Industry leaders can pursue a set of prioritized, actionable recommendations to enhance resilience and accelerate value realization across antisense and RNAi programs. First, integrate delivery and CMC considerations early in the discovery process so that platform choices align with manufacturability, regulatory expectations, and patient administration preferences. Early co-optimization of chemistry and formulation reduces late-stage rework and shortens the path to reproducible, scalable manufacturing. Second, diversify supplier networks and qualify alternate raw material sources to mitigate supply chain risk; scenario planning for tariff-impacted inputs and critical reagents should be embedded into procurement and program risk registers.

Third, pursue collaborative models that leverage specialized CDMOs and research partners to access capacity and technical expertise without overextending capital deployment. Strategic alliances that include shared development milestones and de-risking mechanisms can accelerate timelines while preserving upside for original innovators. Fourth, design clinical programs with payer-relevant endpoints and real-world evidence components that anticipate market access questions earlier in development; this alignment increases the probability of reimbursement and supports broader adoption post-launch. Fifth, invest in regulatory strategy and proactive engagement with authorities to clarify expectations around nonclinical safety, biomarker qualification, and comparability as manufacturing scales. Proactive regulatory planning reduces uncertainty and supports more efficient submission packages.

Finally, prioritize workforce capability building and cross-functional governance to manage complex development portfolios effectively. Establish multidisciplinary teams that align discovery, translational science, CMC, clinical operations, and commercial planning to ensure decisions are made with a holistic view of program risks and opportunities. Collectively, these actions create a practical roadmap for leaders seeking to translate molecular promise into patient impact while controlling development complexity and commercial risk.

Clear research methodology outlining primary and secondary approaches expert interviews and data triangulation applied to antisense and RNAi therapeutic analysis

This analysis is grounded in a mixed-methods research approach that combines primary qualitative insights and rigorous secondary synthesis to create an evidence-based narrative. Primary inputs include structured interviews with subject-matter experts across discovery, CMC, clinical operations, and commercial functions, which offer context on operational challenges, technology adoption curves, and strategic priorities. These conversations were supplemented by targeted consultations with manufacturing leaders and regulatory affairs specialists to ensure practical grounding in scale-up realities and compliance expectations.

Secondary research entailed systematic review of peer-reviewed literature, regulatory guidance documents, public company disclosures, and technical white papers that illuminate technology advances, safety considerations, and clinical trends. Data from diverse sources were triangulated to identify consistent signals, reconcile differences, and highlight areas of emerging consensus or uncertainty. Throughout the process, findings were validated against expert perspectives to refine interpretation, ensure factual accuracy, and surface actionable implications for decision-makers.

Concise synthesis highlighting strategic imperatives key challenges and practical pathways for stakeholders advancing antisense and RNAi therapeutic development

The synthesis presented here underscores a sector at an inflection point: platform and delivery innovations are broadening the clinical applicability of antisense and RNAi modalities even as commercial and operational complexities increase. Key imperatives include aligning platform choices with manufacturability, building resilient supply chains that account for trade and tariff uncertainty, and designing clinical programs that address payer and provider evidence needs. Stakeholders who combine scientific ambition with disciplined operational execution and strategic partnerships will be best positioned to convert technical advances into durable patient and commercial outcomes.

Persistent challenges remain, including tissue-specific delivery beyond canonical targets, long-term safety characterization, and the logistical demands of scalable manufacturing. Nonetheless, by prioritizing early alignment across discovery, CMC, and clinical functions and by proactively managing external risks such as trade policy shifts, organizations can navigate the complexity and capture the value this therapeutic class offers. The conclusion is pragmatic: success will favor those who pair innovation with operational foresight and market-oriented evidence generation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emerging lipid nanoparticle delivery systems enhancing siRNA stability and cellular uptake
• 5.2. Development of ligand conjugation platforms for targeted antisense oligonucleotide therapies
• 5.3. CRISPR-Cas13 mediated RNA editing integration with RNAi therapeutics for precise gene silencing
• 5.4. Utilization of artificial intelligence for optimized antisense sequence design and off-target prediction
• 5.5. Expansion of subcutaneous formulations for RNAi drugs to improve patient compliance and dosing frequency
• 5.6. Clinical progress in antisense therapies for rare neuromuscular disorders with high unmet medical need
• 5.7. Advancements in multivalent siRNA constructs targeting multiple disease pathways in oncology
• 5.8. Regulatory harmonization efforts accelerating global approval of novel RNAi-based therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antisense & RNAi Therapeutics Market, by Oligonucleotide Type

• 8.1. Antisense Oligonucleotides
• 8.2. Interfering RNAi
  • 8.2.1. Micro Interfering RNAs
  • 8.2.2. Small Interfering RNAs

9. Antisense & RNAi Therapeutics Market, by Mode Of Administration

• 9.1. Intrathecal
• 9.2. Intravenous
• 9.3. Oral
• 9.4. Subcutaneous
• 9.5. Topical

10. Antisense & RNAi Therapeutics Market, by Therapeutic Areas

• 10.1. Cardiovascular
• 10.2. Immunology
• 10.3. Metabolic Disorders
• 10.4. Neurological Disorders
• 10.5. Oncology
• 10.6. Ophthalmology
• 10.7. Rare Diseases

11. Antisense & RNAi Therapeutics Market, by End User

• 11.1. Contract Research Organizations
• 11.2. Pharmaceutical Companies
• 11.3. Research Laboratories

12. Antisense & RNAi Therapeutics Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Antisense & RNAi Therapeutics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Antisense & RNAi Therapeutics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Acuitas Therapeutics Inc.
  • 15.3.2. Alloy Therapeutics, Inc.
  • 15.3.3. Alnylam Pharmaceuticals, Inc.
  • 15.3.4. Arbutus Biopharma Corporation
  • 15.3.5. Arrowhead Pharmaceuticals, Inc.
  • 15.3.6. AstraZeneca plc
  • 15.3.7. Bayer AG
  • 15.3.8. Benitec Biopharma Limited
  • 15.3.9. City Therapeutics
  • 15.3.10. Danaher Corporation
  • 15.3.11. Eli Lilly and Company
  • 15.3.12. Evox Therapeutics Ltd
  • 15.3.13. GenScript Biotech Corporation
  • 15.3.14. GSK PLC
  • 15.3.15. Ionis Pharmaceuticals, Inc.
  • 15.3.16. Merck KGaA
  • 15.3.17. Novo Nordisk A/S
  • 15.3.18. Pfizer Inc.
  • 15.3.19. Ribocure Pharmaceuticals AB
  • 15.3.20. Sanofi S.A.
  • 15.3.21. Shanghai Argo Biopharmaceutical Co., Ltd.
  • 15.3.22. Silence Therapeutics plc
  • 15.3.23. Stoke Therapeutics, Inc.
  • 15.3.24. Suzhou Ribo Life Science Co., Ltd.
  • 15.3.25. Wave Life Sciences Ltd

LIST OF FIGURES

• FIGURE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 132. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 133. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 134. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 135. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 136. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 137. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 138. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 139. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 140. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 141. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 142. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 143. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 146. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 147. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 148. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 149. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 150. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 151. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 152. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 153. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 154. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 155. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 158. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 159. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 160. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 161. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 162. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 163. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 164. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 165. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 182. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 183. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 184. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 185. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 186. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 187. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 188. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 189. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 190. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 194. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 195. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 196. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 197. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 198. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 199. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 200. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 201. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 206. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 207. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 208. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 209. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 210. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 211. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 212. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 213. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 214. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 215. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 218. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 219. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 220. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 221. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 222. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 223. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 224. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 225. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 229. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 232. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 233. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 234. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 235. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 236. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 237. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 238. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 239. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 240. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 241. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 244. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 245. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 246. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 247. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 248. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 249. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 250. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 251. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 256. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 257. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 258. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 259. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 260. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 261. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 262. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 263. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 268. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 269. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 270. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 271. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 272. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 273. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 274. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 275. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 276. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 277. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 278. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 279. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 280. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 281. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 282. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 283. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 284. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 285. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 286. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 287. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 288. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 289. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
• TABLE 292. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
• TABLE 293. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
• TABLE 294. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
• TABLE 295. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 296. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 20